What is TAP?

The Treatment Access Platform (TAP) is an innovative solution designed to solve several major problems within the medical care industry; especially as patients have difficulty accessing new and applicable treatments.

The TAP follows Thai FDA regulations and provides new provisional medical care to patients through a limited number of qualified Tier 1 hospitals during early stages of technology market release.

In parallel with operating the TAP, ABC will continue its R&D and clinical trials for new therapeutics and diagnostics.

Why TAP?

Lower Risk. Genuine Need of Treatments & Diagnostics. Higher Success Rate
Drug development has long faced significant challenges with prolonged development cycles (10-15 years) and low success rates in penetrating markets. Bringing a new drug from its discovery phase to a safe, effective, and FDA-approved treatment involves a number of important checkpoints and typically require multi-hundred-million-dollar investments. Even so, only 1 in 5,000 drug candidates reach the commercial market, as pharmaceutical companies face greater possibilities of generating insufficient returns on their investments.

To account for the economic benefits and risks of developing a new drug, traditional pharmaceutical companies are left with seeking ONLY large addressable markets AND charging high premiums for the newly-developed interventions in order to recover their spending in R&D, regulations, and marketing. Naturally, USA and EU, with their large population sizes and high levels of medical expenditures, become the primary markets for all new medical innovations.

Using the unique and innovative fundraising strategy of an initial coin offering (ICO), ABC can meaningfully address such problems of market limitations and high drug costs caused by the pursuit of return of investment. More importantly, the TAP will grant participants exclusive and guaranteed access to treatments and diagnostics in early stage of market release.

What Technologies
will be Available on the TAP?

The TAP will provide technologies for cancers, neurological diseases, infectious diseases, vascular diseases, and metabolic diseases. ABC supports innovative diagnostics and various treatment modalities such as: gene and cell therapy, vaccines, and immunotherapy.

How to
participate
in TAP?

CONTACT US TO EXPLORE A PARTNERSHIP

Ascendant Biotech Corporation Ltd.

158/5 Aneckvanich Building (Rooms AC, 5th Floor) Sukhumvit 55 Road, Khlong Tan Nuea, Vadhana, Bangkok 10110

STAY TUNED FOR OUR LAUNCH ANNOUNCEMENT VIA

COPYRIGHT © 2020 ASCENDANT BIOTECH CORPORATION LIMITED